Glück Conviction Score™ ⓘ
AORT
ARTIVION, INC.
Effektiv: Risiko-Ausstieg
Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
36,8
33 neu, 95 erhöht, -358855K $ netto
Aktivist
17,7
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bärisch | 10 % | 29.22 | -31.2 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 38.79 | -48.2 % vs SMA200 | |
| SMA-Cross | Bärisch | 10 % | DEATH | vor 59 Tagen @ 36.53 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 22.46 | EMA50: 27.33 | |
| MACD-Histogramm | Bullisch | 10 % | 0.368 | Bullisch | |
| RSI(14) | Bullisch | 10 % | 28.1 | Überverkauft | |
| Stoch %K(14) | Bullisch | 5 % | 7.4 | Überverkauft | |
| ADX(14)+DI | Bärisch | 10 % | 47.0 | +DI: 13.8 / −DI: 35.2 | |
| Z-Score(60) | Neutral | 5 % | -1.44 | In Range | |
| 52W-Position | Bärisch | 5 % | 0.0 % | Hoch 47.63 / Tief 20.10 | |
| Bollinger(20,2σ) | Bullisch | 5 % | 16.7 % | Upper 24.02 / Mid 21.67 / Lower 19.31 | |
| LinReg-Slope(60) | Bärisch | 10 % | -0.3537 | R²=0.74 / annualisiert -294.1 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -8.962 | 38,00 | -340.556,00 | -102,7% | |
| 2026-03-03 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -901 | 37,78 | -34.035,82 | -10,3% | |
| 2026-03-03 | Mackin James P | Officer, President & CEO | Open Market Sale | -17.887 | 37,78 | -675.692,16 | -203,8% | |
| 2026-03-03 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -3.843 | 37,78 | -145.171,63 | -43,8% | |
| 2026-03-03 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -4.573 | 37,78 | -172.747,82 | -52,1% | |
| 2026-03-03 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2.149 | 37,78 | -81.179,76 | -24,5% | |
| 2026-03-03 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -6.316 | 37,78 | -238.590,69 | -72,0% | |
| 2026-03-02 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -641 | 38,02 | -24.373,96 | -7,4% | |
| 2026-03-02 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1.513 | 38,02 | -57.531,67 | -17,4% | |
| 2026-03-02 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -2.784 | 38,02 | -105.861,32 | -31,9% | |
| 2026-03-02 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -5.178 | 38,02 | -196.892,93 | -59,4% | |
| 2026-03-02 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -2.183 | 38,02 | -83.008,36 | -25,0% | |
| 2026-03-02 | Mackin James P | Officer, President & CEO | Open Market Sale | -14.911 | 38,02 | -566.989,28 | -171,0% | |
| 2026-02-24 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -4.485 | 35,69 | -160.083,11 | -48,3% | |
| 2026-02-24 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -1.668 | 35,69 | -59.535,92 | -18,0% | |
| 2026-02-24 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -2.075 | 35,69 | -74.062,98 | -22,3% | |
| 2026-02-24 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1.259 | 35,69 | -44.937,49 | -13,6% | |
| 2026-02-24 | Mackin James P | Officer, President & CEO | Open Market Sale | -13.936 | 35,69 | -497.417,65 | -150,0% | |
| 2026-02-24 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -830 | 35,69 | -29.625,19 | -8,9% | |
| 2026-02-23 | Mackin James P | Officer, President & CEO | Open Market Sale | -20.962 | 37,59 | -787.919,66 | -237,6% | |
| 2026-02-23 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -3.773 | 37,59 | -141.819,52 | -42,8% | |
| 2026-02-23 | Berry Lance A | Officer, EVP, COO, CFO & Treasurer | Open Market Sale | -4.981 | 37,59 | -187.225,83 | -56,5% | |
| 2026-02-23 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -1.731 | 37,59 | -65.064,83 | -19,6% | |
| 2026-02-23 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -3.079 | 37,59 | -115.733,45 | -34,9% | |
| 2026-02-23 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2.423 | 37,59 | -91.075,72 | -27,5% | |
| 2025-12-15 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -5.000 | 45,11 | -225.550,00 | -68,0% | |
| 2025-12-08 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -4.572 | 44,42 | -203.083,67 | -61,2% | |
| 2025-12-03 | Mackin James P | Officer, President & CEO | Open Market Sale | -30.921 | 45,46 | -1.405.699,58 | -423,9% | |
| 2025-12-03 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -5.267 | 45,30 | -238.595,10 | -72,0% | |
| 2025-12-03 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -2.048 | 45,30 | -92.774,40 | -28,0% | |
| 2025-12-02 | Mackin James P | Officer, President & CEO | Open Market Sale | -30.921 | 45,56 | -1.408.729,84 | -424,9% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -14.586 | 44,92 | -655.188,53 | -197,6% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -8.370 | 45,35 | -379.537,65 | -114,5% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -5.715 | 45,35 | -259.152,39 | -78,2% | |
| 2025-11-21 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -18.705 | 44,91 | -840.041,55 | -253,3% | |
| 2025-11-20 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -11.888 | 44,14 | -524.736,32 | -158,3% | |
| 2025-11-20 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1.355 | 44,28 | -59.996,69 | -18,1% | |
| 2025-11-20 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2.033 | 44,32 | -90.092,40 | -27,2% | |
| 2025-11-18 | Hoff Elizabeth A | Director | Open Market Sale | -4.200 | 45,10 | -189.411,60 | -57,1% | |
| 2025-11-17 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -6.394 | 45,17 | -288.816,98 | -87,1% | |
| 2025-11-17 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -6.394 | 45,17 | -288.816,98 | -87,1% | |
| 2025-11-17 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -6.000 | 45,73 | -274.380,00 | -82,7% | |
| 2025-11-14 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -6.393 | 44,67 | -285.575,31 | -86,1% | |
| 2025-11-14 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -6.393 | 45,00 | -287.685,00 | -86,8% | |
| 2025-11-13 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -4.993 | 45,86 | -228.968,99 | -69,1% | |
| 2025-11-13 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -5.761 | 45,86 | -264.187,94 | -79,7% | |
| 2025-11-13 | Mackin James P | Officer, President & CEO | Open Market Sale | -34.210 | 45,86 | -1.568.802,18 | -473,1% | |
| 2025-11-13 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -6.563 | 45,86 | -300.966,05 | -90,8% | |
| 2025-11-13 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -3.482 | 45,86 | -159.677,56 | -48,2% | |
| 2025-11-11 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -10.000 | 46,18 | -461.800,00 | -139,3% | |
| 2025-11-10 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -2.960 | 44,62 | -132.072,24 | -39,8% | |
| 2025-11-10 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -2.566 | 44,62 | -114.492,35 | -34,5% | |
| 2025-11-10 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -1.789 | 44,62 | -79.823,39 | -24,1% | |
| 2025-11-10 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -3.373 | 44,62 | -150.499,89 | -45,4% | |
| 2025-11-10 | Mackin James P | Officer, President & CEO | Open Market Sale | -17.580 | 44,62 | -784.402,02 | -236,6% | |
| 2025-08-27 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -18.200 | 44,02 | -801.218,60 | -241,6% | |
| 2025-08-25 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -10.000 | 44,37 | -443.700,00 | -133,8% | |
| 2025-08-15 | Mackin James P | Officer, President & CEO | Open Market Sale | -12.500 | 42,32 | -528.987,50 | -159,5% | |
| 2025-08-12 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -6.381 | 43,02 | -274.497,86 | -82,8% | |
| 2025-08-12 | Davis John E | Officer, Chief Commercial Officer | Open Market Sale | -10.802 | 43,67 | -471.755,75 | -142,3% | |
| 2025-08-12 | Holloway Jean F | Officer, SVP, General Counsel | Open Market Sale | -16.975 | 43,01 | -730.111,73 | -220,2% | |
| 2025-08-08 | Horton Amy | Officer, VP, Chief Accounting Officer | Open Market Sale | -7.992 | 38,49 | -307.612,08 | -92,8% | |
| 2025-06-17 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -13.764 | 29,50 | -406.038,00 | -122,5% | |
| 2025-06-17 | Stanton Marshall S. | Officer, SVP, Clinical & MD Affair | Open Market Sale | -1.236 | 29,50 | -36.462,00 | -11,0% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 6.474.854 | 6.368.119 | 106.735 | 237.109.138 | Aufgestockt | +1,7% | |
| VANGUARD GROUP INC | 3.170.089 | 0 | 3.170.089 | 144.587.760 | Neu | +100,0% | |
| FMR LLC | 2.583.427 | 2.541.867 | 41.560 | 94.605.113 | Aufgestockt | +1,6% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2.456.146 | 2.613.471 | -157.325 | 89.944.000 | Reduziert | -6,0% | |
| MORGAN STANLEY | 2.269.294 | 2.256.742 | 12.552 | 83.101.577 | Aufgestockt | +0,6% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.952.008 | 0 | 1.952.008 | 71.482.533 | Neu | +100,0% | |
| STATE STREET CORP | 1.682.273 | 1.584.920 | 97.353 | 61.604.837 | Aufgestockt | +6,1% | |
| PERCEPTIVE ADVISORS LLC | 1.637.290 | 1.722.290 | -85.000 | 59.957.560 | Reduziert | -4,9% | |
| FRED ALGER MANAGEMENT, LLC | 1.208.371 | 1.372.572 | -164.201 | 44.250.546 | Reduziert | -12,0% | |
| Juniper Investment Company, LLC | 1.189.136 | 1.189.136 | 0 | 43.546.160 | Unverändert | 0,0% | |
| Conestoga Capital Advisors, LLC | 1.175.410 | 0 | 1.175.410 | 43.043.514 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 1.156.687 | 1.405.409 | -248.722 | 42.357.878 | Reduziert | -17,7% | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.132.503 | 998.327 | 134.176 | 41.479.999 | Aufgestockt | +13,4% | |
| DIMENSIONAL FUND ADVISORS LP | 1.027.575 | 980.837 | 46.738 | 37.626.413 | Aufgestockt | +4,8% | |
| NEXT CENTURY GROWTH INVESTORS LLC | 1.023.701 | 1.044.395 | -20.694 | 37.487.930 | Reduziert | -2,0% | |
| LOOMIS SAYLES & CO L P | 980.439 | 840.062 | 140.377 | 35.903.676 | Aufgestockt | +16,7% | |
| Ophir Asset Management Pty Ltd | 950.850 | 0 | 950.850 | 34.820.127 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 725.852 | 443.467 | 282.385 | 26.580.700 | Aufgestockt | +63,7% | |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 660.941 | 584.942 | 75.999 | 24.203.659 | Aufgestockt | +13,0% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 517.479 | 0 | 517.479 | 23.602.217 | Neu | +100,0% | |
| YARGER WEALTH STRATEGIES, LLC | 634.223 | 0 | 634.223 | 23.225.246 | Neu | +100,0% | |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 605.722 | 863.867 | -258.145 | 22.181.540 | Reduziert | -29,9% | |
| BANK OF AMERICA CORP /DE/ | 522.515 | 518.535 | 3.980 | 19.134.506 | Aufgestockt | +0,8% | |
| NORTHERN TRUST CORP | 497.899 | 472.761 | 25.138 | 18.233.063 | Aufgestockt | +5,3% | |
| ROYCE & ASSOCIATES LP | 425.282 | 432.782 | -7.500 | 15.573.827 | Reduziert | -1,7% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 405.773 | 407.378 | -1.605 | 14.859.407 | Reduziert | -0,4% | |
| Invesco Ltd. | 375.046 | 1.101.239 | -726.193 | 13.734.184 | Reduziert | -65,9% | |
| PEREGRINE CAPITAL MANAGEMENT LLC | 342.795 | 295.721 | 47.074 | 12.553.153 | Aufgestockt | +15,9% | |
| First Eagle Investment Management, LLC | 311.601 | 306.893 | 4.708 | 11.410.828 | Aufgestockt | +1,5% | |
| GOLDMAN SACHS GROUP INC | 306.277 | 537.375 | -231.098 | 11.215.864 | Reduziert | -43,0% | |
| KENNEDY CAPITAL MANAGEMENT LLC | 299.348 | 438.745 | -139.397 | 10.962.124 | Reduziert | -31,8% | |
| TWO SIGMA ADVISERS, LP | 218.700 | 0 | 218.700 | 9.974.907 | Neu | +100,0% | |
| PRINCIPAL FINANCIAL GROUP INC | 261.370 | 240.449 | 20.921 | 9.571.368 | Aufgestockt | +8,7% | |
| UBS Group AG | 256.922 | 279.675 | -22.753 | 9.408.484 | Reduziert | -8,1% | |
| Parkman Healthcare Partners LLC | 252.014 | 218.669 | 33.345 | 9.228.753 | Aufgestockt | +15,2% | |
| OSTERWEIS CAPITAL MANAGEMENT INC | 240.217 | 220.727 | 19.490 | 8.796.747 | Aufgestockt | +8,8% | |
| OBERWEIS ASSET MANAGEMENT INC/ | 221.122 | 217.060 | 4.062 | 8.097.488 | Aufgestockt | +1,9% | |
| Qube Research & Technologies Ltd | 201.323 | 19.879 | 181.444 | 7.372.448 | Aufgestockt | +912,7% | |
| Tidal Investments LLC | 192.793 | 197.723 | -4.930 | 7.060.080 | Reduziert | -2,5% | |
| AMERIPRISE FINANCIAL INC | 191.730 | 141.234 | 50.496 | 7.021.153 | Aufgestockt | +35,8% | |
| Summit Creek Advisors LLC | 189.137 | 140.873 | 48.264 | 6.926.197 | Aufgestockt | +34,3% | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 187.854 | 196.978 | -9.124 | 6.879.213 | Reduziert | -4,6% | |
| Legal & General Group Plc | 185.071 | 190.748 | -5.677 | 6.777.301 | Reduziert | -3,0% | |
| SEI INVESTMENTS CO | 168.012 | 114.284 | 53.728 | 6.152.597 | Aufgestockt | +47,0% | |
| WASATCH ADVISORS LP | 156.388 | 204.443 | -48.055 | 5.726.929 | Reduziert | -23,5% | |
| FIRST TRUST ADVISORS LP | 151.399 | 136.521 | 14.878 | 5.544.231 | Aufgestockt | +10,9% | |
| ORBIMED ADVISORS LLC | 151.000 | 0 | 151.000 | 5.529.620 | Neu | +100,0% | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | 150.663 | 144.308 | 6.355 | 5.517.279 | Aufgestockt | +4,4% | |
| JPMORGAN CHASE & CO | 114.363 | 0 | 114.363 | 5.216.096 | Neu | +100,0% | |
| Universal- Beteiligungs- und Servicegesellschaft mbH | 139.858 | 138.558 | 1.300 | 5.121.600 | Aufgestockt | +0,9% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6.474.854 | 6.368.119 | +1,7% | 237.109.138 | 15,59 |
| FMR LLC | 2.583.427 | 2.541.867 | +1,6% | 94.605.113 | 6,22 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2.456.146 | 2.613.471 | -6,0% | 89.944.000 | 5,91 |
| MORGAN STANLEY | 2.269.294 | 2.256.742 | +0,6% | 83.101.577 | 5,46 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.952.008 | 0 | +100,0% | 71.482.533 | 4,70 |
| STATE STREET CORP | 1.682.273 | 1.584.920 | +6,1% | 61.604.837 | 4,05 |
| PERCEPTIVE ADVISORS LLC | 1.637.290 | 1.722.290 | -4,9% | 59.957.560 | 3,94 |
| FRED ALGER MANAGEMENT, LLC | 1.208.371 | 1.372.572 | -12,0% | 44.250.546 | 2,91 |
| Juniper Investment Company, LLC | 1.189.136 | 1.189.136 | 0,0% | 43.546.160 | 2,86 |
| Conestoga Capital Advisors, LLC | 1.175.410 | 0 | +100,0% | 43.043.514 | 2,83 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.156.687 | 1.405.409 | -17,7% | 42.357.878 | 2,78 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.132.503 | 998.327 | +13,4% | 41.479.999 | 2,73 |
| DIMENSIONAL FUND ADVISORS LP | 1.027.575 | 980.837 | +4,8% | 37.626.413 | 2,47 |
| NEXT CENTURY GROWTH INVESTORS LLC | 1.023.701 | 1.044.395 | -2,0% | 37.487.930 | 2,46 |
| LOOMIS SAYLES & CO L P | 980.439 | 840.062 | +16,7% | 35.903.676 | 2,36 |
| Ophir Asset Management Pty Ltd | 950.850 | 0 | +100,0% | 34.820.127 | 2,29 |
| TWO SIGMA INVESTMENTS, LP | 725.852 | 443.467 | +63,7% | 26.580.700 | 1,75 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 660.941 | 584.942 | +13,0% | 24.203.659 | 1,59 |
| YARGER WEALTH STRATEGIES, LLC | 634.223 | 0 | +100,0% | 23.225.246 | 1,53 |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 605.722 | 863.867 | -29,9% | 22.181.540 | 1,46 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 238 | 48,1 | 1.716 |
| 31.12.2025 | ✓ | 240 | 45,7 | 2.008 |
| 30.09.2025 | ✓ | 221 | 45,2 | 1.839 |
| 30.06.2025 | ✓ | 189 | 41,9 | 1.245 |
| 31.03.2025 | ✓ | 188 | 132,9 | 1.266 |
| 31.12.2024 | ✓ | 179 | 124,2 | 1.245 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2.613.471 | 119.200.000 |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 863.867 | 39.400.974 |
| Summit Creek Advisors LLC | 140.873 | 6.425.218 |
| Mariner, LLC | 40.263 | 1.836.102 |
| POLEN CAPITAL MANAGEMENT LLC | 25.259 | 1.152.063 |
| GUGGENHEIM CAPITAL LLC | 22.082 | 1.007.160 |
| XTX Topco Ltd | 16.363 | 746.316 |
| STIFEL FINANCIAL CORP | 15.854 | 723.101 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 9.777 | 446.321 |
| SHEETS SMITH WEALTH MANAGEMENT | 8.919 | 406.796 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| Invesco Ltd. | 1.101.239 | 748.119 | +211.9 % | 50.227.510 |
| BlackRock, Inc. | 6.368.119 | 318.474 | +5.3 % | 290.449.888 |
| GOLDMAN SACHS GROUP INC | 537.375 | 317.518 | +144.4 % | 24.509.674 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 517.479 | 261.956 | +102.5 % | 23.602.217 |
| LOOMIS SAYLES & CO L P | 840.062 | 217.860 | +35.0 % | 38.315.227 |
| VANGUARD GROUP INC | 3.170.089 | 141.030 | +4.7 % | 144.587.760 |
| Nuveen, LLC | 169.841 | 87.403 | +106.0 % | 7.746.448 |
| UBS Group AG | 279.675 | 75.606 | +37.0 % | 12.755.978 |
| GEODE CAPITAL MANAGEMENT, LLC | 998.327 | 66.709 | +7.2 % | 45.541.799 |
| TWO SIGMA ADVISERS, LP | 218.700 | 62.000 | +39.6 % | 9.974.907 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| FMR LLC | 2.541.867 | -446.294 | -14.9 % | 115.934.546 |
| PERCEPTIVE ADVISORS LLC | 1.722.290 | -297.710 | -14.7 % | 78.553.647 |
| JANE STREET GROUP, LLC | 10.347 | -273.447 | -96.4 % | 471.926 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 584.942 | -171.059 | -22.6 % | 26.679.205 |
| Juniper Investment Company, LLC | 1.189.136 | -144.556 | -10.8 % | 54.236.493 |
| ROYCE & ASSOCIATES LP | 432.782 | -96.965 | -18.3 % | 19.739.187 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.405.409 | -95.676 | -6.4 % | 64.100.705 |
| GW&K Investment Management, LLC | 753.752 | -90.155 | -10.7 % | 34.379 |
| LORD, ABBETT & CO. LLC | 584.165 | -86.061 | -12.8 % | 26.644 |
| Trexquant Investment LP | 4.923 | -79.697 | -94.2 % | 224.538 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -6,41 pp | |
| 17.02.2026 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | Passiv (13G) | 5,50 % | 2.613.471 | Neu | |
| 17.02.2026 | NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | Passiv (13G) | 5,50 % | 2.613.471 | Neu | |
| 13.02.2026 | Macquarie Group Limited | Passiv (13G/A) | Ausstieg | 0 | -5,26 pp | |
| 13.02.2026 | Macquarie Management Holdings Inc | Passiv (13G/A) | Ausstieg | 0 | -5,26 pp | |
| 13.02.2026 | Macquarie Investment Management Business Trust | Passiv (13G/A) | Ausstieg | 0 | -5,26 pp | |
| 14.11.2025 | Perceptive Life Sciences Master Fund, Ltd. | Passiv (13G/A) | 4,30 % | 2.020.000 | Neu | |
| 14.11.2025 | Perceptive Advisors LLC | Passiv (13G/A) | 4,30 % | 2.020.000 | Neu | |
| 14.11.2025 | Joseph Edelman | Passiv (13G/A) | 4,30 % | 2.020.000 | Neu | |
| 13.11.2025 | Macquarie Group Limited | Passiv (13G/A) | 5,26 % | 2.483.842 | -1,34 pp | |
| 13.11.2025 | Macquarie Investment Management Business Trust | Passiv (13G/A) | 5,26 % | 2.483.842 | -1,34 pp | |
| 13.11.2025 | Macquarie Management Holdings Inc | Passiv (13G/A) | 5,26 % | 2.483.842 | -1,34 pp | |
| 07.11.2025 | Morgan Stanley | Passiv (13G/A) | 4,40 % | 2.074.975 | -1,40 pp | |
| 17.10.2025 | BlackRock, Inc. | Passiv (13G/A) | 12,70 % | 5.977.264 | -1,20 pp | |
| 12.08.2025 | Alexis P. Michas | Aktivist (13D/A) | 4,00 % | 1.864.449 | -1,20 pp | Item 4 is hereby amended and supplemented by adding the following information. Between … |
| 12.08.2025 | John A. Bartholdson | Aktivist (13D/A) | 4,00 % | 1.864.449 | -1,20 pp | Item 4 is hereby amended and supplemented by adding the following information. Between … |
| 12.08.2025 | Juniper HF Investors II, LLC | Aktivist (13D/A) | 3,10 % | 1.473.656 | -0,60 pp | Item 4 is hereby amended and supplemented by adding the following information. Between … |
| 12.08.2025 | Juniper HF Investors, LLC | Aktivist (13D/A) | 0,00 % | 13.485 | 0,00 pp | Item 4 is hereby amended and supplemented by adding the following information. Between … |
| 12.08.2025 | Juniper Targeted Opportunity Fund, L.P. | Aktivist (13D/A) | 3,10 % | 1.473.656 | -0,60 pp | Item 4 is hereby amended and supplemented by adding the following information. Between … |
| 12.08.2025 | Juniper Investment Company, LLC | Aktivist (13D/A) | 4,00 % | 1.864.449 | -1,20 pp | Item 4 is hereby amended and supplemented by adding the following information. Between … |
| 12.08.2025 | Juniper Multi-Strategy Fund, L.P. | Aktivist (13D/A) | 0,00 % | 13.485 | 0,00 pp | Item 4 is hereby amended and supplemented by adding the following information. Between … |
| 12.08.2025 | Juniper Targeted Opportunity Investors, LLC | Aktivist (13D/A) | 0,80 % | 377.308 | -0,70 pp | Item 4 is hereby amended and supplemented by adding the following information. Between … |
| 12.08.2025 | Juniper Targeted Opportunities, L.P. | Aktivist (13D/A) | 0,80 % | 377.308 | -0,70 pp | Item 4 is hereby amended and supplemented by adding the following information. Between … |
| 06.08.2025 | FMR LLC | Passiv (13G/A) | 5,40 % | 2.288.030 | -1,50 pp | |
| 06.08.2025 | Abigail P. Johnson | Passiv (13G/A) | 5,40 % | 2.288.030 | -1,50 pp | |
| 21.07.2025 | BlackRock, Inc. | Passiv (13G/A) | 13,90 % | 5.950.909 | Neu | |
| 12.05.2025 | FMR LLC | Passiv (13G) | 6,90 % | 2.900.842 | Neu | |
| 12.05.2025 | Abigail P. Johnson | Passiv (13G) | 6,90 % | 2.900.842 | Neu | |
| 08.11.2024 | . BlackRock, Inc. | Passiv (13G/A) | 15,60 % | 6.514.785 | 0,00 pp | |
| 08.11.2024 | Wellington Investment Advisors Holdings LLP | Passiv (13G/A) | 3,95 % | 1.656.264 | -2,04 pp | |
| 08.11.2024 | Wellington Management Group LLP | Passiv (13G/A) | 3,95 % | 1.656.264 | -2,04 pp | |
| 08.11.2024 | Wellington Group Holdings LLP | Passiv (13G/A) | 3,95 % | 1.656.264 | -2,04 pp | |
| 18.10.2024 | . BlackRock, Inc. | Passiv (13G/A) | 15,60 % | 6.514.785 | -1,10 pp | |
| 11.03.2024 | Perceptive Advisors LLC | Passiv (13G) | 5,80 % | 2.383.978 | Neu | |
| 11.03.2024 | Joseph Edelman | Passiv (13G) | 5,80 % | 2.383.978 | Neu | |
| 11.03.2024 | Perceptive Life Sciences Master Fund, Ltd. | Passiv (13G) | 5,80 % | 2.383.978 | Neu | |
| 14.02.2024 | Macquarie Management Holdings Inc | Passiv (13G/A) | 7,00 % | 2.873.431 | Neu | |
| 14.02.2024 | Macquarie Investment Management Business Trust | Passiv (13G/A) | 7,00 % | 2.873.431 | Neu | |
| 14.02.2024 | Macquarie Group Limited | Passiv (13G/A) | 7,00 % | 2.873.431 | Neu | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 6,41 % | 2.630.873 | -0,56 pp |
Stammdaten
Artivion Inc. stellt medizinische Geräte her, verarbeitet diese und vertreibt sie weltweit. Das Unternehmen bietet BioGlue an, ein Polymer aus Rinderblutprotein und einem Protein-Vernetzungsmittel für kardiale, vaskuläre, neurologische und pulmonale Verfahren; Herzkonservierungsdienste; PhotoFix, ein Rindperikardflicken; und E-vita Open Plus und E-vita Open Neo. Es bietet auch E-xtra-Design-Engineering-Systeme zur Behandlung von Aortengefäßerkrankungen; E-nside, ein Standardstentgraft zur Behandlung thorakoabdominaler Erkrankungen; E-vita THORACIC 3G zur endovaskulären Behandlung thorakaler Aortenaneurysmen; E-nya, ein thorakales Stentgraft-System zur minimalinvasiven Reparatur von Läsionen der absteigenden Aorta; E-ventus BX, ein ballonexpandierbares peripheres Stentgraft zur endovaskulären Behandlung von Nieren- und Beckengefäßen; E-liac zur Behandlung aneurysmatischer Iliacagefäße und aneurysmatischer Iliacaseitenzweige; und E-tegra, ein Bauchaorenaneursymen-Stentgraft-System. Darüber hinaus bietet das Unternehmen synthetische Gefäßtransplantate zur Verwendung in offenen Aorten- und peripheralen Gefäßchirurgieverfahren; PerClot, ein resorbierbares pulverisiertes Hämostatikum zur Verwendung in chirurgischen Verfahren; kardiale Lasertherapieprodukte zur Angina-Behandlung; CryoVein-Oberschenkelvenen- und CryoArtery-Oberschenkelarterie-Gefäßkonservierungsdienste; On-X-Kunstklappen für Aorta und Mitralklappe und die On-X-Aorta-Kunstventilumsatz; CarbonAid-CO2-Diffusionskatheter und Chord-X-ePTFE-Nähte zur Mitralklappenakkordersatzung; sowie ascyrus-medizinische Dissektion-Stents und pyrolytische Kohlenstoffbeschichtungsdienste für Medizinproduktehersteller. Es bedient Ärzte, Krankenhäuser und andere Gesundheitseinrichtungen sowie Kardio-, Gefäß-, Thorax- und Allgemeinchirurgen. Das Unternehmen war früher als CryoLife, Inc. bekannt und änderte seinen Namen im Januar 2022 in Artivion Inc. Das Unternehmen wurde 1984 gegründet und hat seinen Hauptsitz in Kennesaw, Georgia.
Unternehmen & Branche
| Name | ARTIVION, INC. |
|---|---|
| Ticker | AORT |
| CIK | 0000784199 |
| Boerse | NYSE |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | 228903100 |
|---|---|
| ISIN | US2289031005 |
| Typ | Common Stock |
| Marktkapitalisierung | 965,4 Mio. USD |
| KGV (P/E) | 97,48 |
| Beta | 1,37 |
| Dividendenrendite | 0,00 % |
Bewertung
| KBV (P/B) | 2,15 vs. 2,64 (2021) ▼ |
|---|---|
| KUV (P/S) | 2,19 vs. 2,65 (2021) ▼ |
| EV/EBITDA | 20,6 vs. 34,3 (2021) ▼ |
| FCF-Rendite | 0,1 % vs. -2,0 % (2021) ▲ |
Qualität & Bilanz
| Bruttomarge | 64,4 % vs. 66,1 % (2021) ▼ |
|---|---|
| Operative Marge | 7,6 % vs. 2,7 % (2021) ▲ |
| Nettomarge | 2,2 % vs. -5,0 % (2021) ▲ |
| ROIC | 1,4 % vs. -2,2 % (2021) ▲ |
| Nettoverschuldung/EBITDA | 3,4 vs. 9,6 (2021) ▼ |
| Zinsdeckungsgrad | 1,3 vs. 0,5 (2021) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 2,64 | 1,71 | 2,59 | 4,31 | 4,80 | |
| KUV (P/S) | 2,65 | 1,55 | 2,06 | 3,07 | 4,87 | |
| EV/EBITDA | 34,3 | 28,0 | 35,7 | 23,8 | 41,7 | |
| FCF-Rendite | -2,0 % | -3,3 % | 1,2 % | 0,9 % | 0,0 % | |
| Qualität & Bilanz | ||||||
| Bruttomarge | 66,1 % | 64,5 % | 64,7 % | 64,0 % | 64,4 % | |
| Operative Marge | 2,7 % | 2,0 % | 1,6 % | 10,0 % | 7,6 % | |
| Nettomarge | -5,0 % | -6,1 % | -8,7 % | -3,4 % | 2,2 % | |
| ROIC | -2,2 % | -3,0 % | -4,8 % | -2,1 % | 1,4 % | |
| Nettoverschuldung/EBITDA | 9,6 | 11,1 | 10,4 | 4,9 | 3,4 | |
| Zinsdeckungsgrad | 0,5 | 0,3 | 0,2 | 1,1 | 1,3 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 116.337.000 | 1.417.000 | 0,03 | 883.157.000 | 450.467.000 |
| 2025-12-31 | 10-K | 441.330.000 | 9.768.000 | 0,21 | 884.796.000 | 448.232.000 |
| 2025-09-30 | 10-Q | 113.388.000 | 6.502.000 | 0,13 | 857.662.000 | 438.694.000 |
| 2025-06-30 | 10-Q | 112.972.000 | 1.345.000 | 0,03 | 838.387.000 | 419.902.000 |
| 2025-03-31 | 10-Q | 98.978.000 | -505.000 | -0,01 | 791.163.000 | 294.252.000 |
| 2024-12-31 | 10-K | 388.537.000 | -13.359.000 | -0,32 | 789.101.000 | 276.200.000 |
| 2024-09-30 | 10-Q | 95.779.000 | -2.288.000 | -0,05 | 803.144.000 | 304.739.000 |
| 2024-06-30 | 10-Q | 98.019.000 | -2.121.000 | -0,05 | 789.539.000 | 295.056.000 |
| 2024-03-31 | 10-Q | 97.431.000 | 7.533.000 | 0,18 | 784.007.000 | 294.985.000 |
| 2023-12-31 | 10-K | 354.004.000 | -30.690.000 | -0,75 | 792.397.000 | 281.780.000 |
| 2023-09-30 | 10-Q | 87.854.000 | -9.801.000 | -0,24 | 774.787.000 | 271.975.000 |
| 2023-06-30 | 10-Q | 89.251.000 | -3.382.000 | -0,08 | 777.861.000 | 282.508.000 |
| 2023-03-31 | 10-Q | 83.229.000 | -13.532.000 | -0,33 | 757.073.000 | 279.917.000 |
| 2022-12-31 | 10-K | 313.789.000 | -19.192.000 | -0,48 | 762.798.000 | 284.329.000 |
| 2022-09-30 | 10-Q | 76.838.000 | -13.713.000 | -0,34 | 742.731.000 | 255.108.000 |
| 2022-06-30 | 10-Q | 80.340.000 | -4.259.000 | -0,11 | 764.864.000 | 281.509.000 |
| 2022-03-31 | 10-Q | 77.213.000 | -3.389.000 | -0,08 | 781.856.000 | 297.492.000 |
| 2021-12-31 | 10-K | 298.836.000 | -14.834.000 | -0,38 | 793.052.000 | 300.728.000 |
| 2021-09-30 | 10-Q | 72.207.000 | 10.582.000 | 0,26 | 818.654.000 | 311.541.000 |
| 2021-06-30 | 10-Q | 76.148.000 | -2.178.000 | -0,06 | 810.497.000 | 301.835.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Products | 345,8 Mio. | 290,2 Mio. | 261,2 Mio. | 230,4 Mio. | 221,6 Mio. | 43,9 % | +19,2% | |
| Aortic Stent Grafts | 159,4 Mio. | 123,1 Mio. | 107,5 Mio. | 92,8 Mio. | – | 20,2 % | +29,5% | |
| On X | 101,7 Mio. | 84,0 Mio. | 74,5 Mio. | 63,9 Mio. | 57,4 Mio. | 12,9 % | +21,1% | |
| Preservation Services | 95,5 Mio. | 98,3 Mio. | 92,8 Mio. | 83,4 Mio. | 77,2 Mio. | 12,1 % | -2,9% | |
| Surgical Sealants | 76,6 Mio. | 73,9 Mio. | 68,0 Mio. | 65,4 Mio. | 70,7 Mio. | 9,7 % | +3,7% | |
| Other Products | 8,1 Mio. | 9,3 Mio. | 11,2 Mio. | 8,3 Mio. | 8,1 Mio. | 1,0 % | -12,5% | |
| Aortic Stents And Stent Grafts | – | – | – | – | 85,4 Mio. | – | – |
Regionen
| Region | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Non Us | 227,3 Mio. | 198,5 Mio. | 174,5 Mio. | 152,7 Mio. | 147,7 Mio. | 51,5 % | +14,5% | |
| US | 214,1 Mio. | 190,0 Mio. | 179,5 Mio. | 161,1 Mio. | 151,2 Mio. | 48,5 % | +12,7% |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 08.05.2026 | 116,3 Mio. USD | 0,03 |
| Q3 2025 | 30.09.2025 | 07.11.2025 | 113,4 Mio. USD | 0,13 |
| Q2 2025 | 30.06.2025 | 08.08.2025 | 113,0 Mio. USD | 0,03 |
| Q1 2025 | 31.03.2025 | 08.05.2026 | 99,0 Mio. USD | -0,01 |
| Q3 2024 | 30.09.2024 | 07.11.2025 | 95,8 Mio. USD | -0,05 |
| Q2 2024 | 30.06.2024 | 08.08.2025 | 98,0 Mio. USD | -0,05 |
| Q1 2024 | 31.03.2024 | 06.05.2025 | 97,4 Mio. USD | 0,18 |
| Q3 2023 | 30.09.2023 | 08.11.2024 | 87,9 Mio. USD | -0,24 |
| Q2 2023 | 30.06.2023 | 09.08.2024 | 89,3 Mio. USD | -0,08 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 08.05.2026 | 10-Q | – | – | SEC » |
| 18.02.2026 | 10-K | 31.12.2025 | 49 Tage | SEC » |
| 07.11.2025 | 10-Q | 30.09.2025 | 38 Tage | SEC » |
| 08.08.2025 | 10-Q | 30.06.2025 | 39 Tage | SEC » |
| 06.05.2025 | 10-Q | 31.03.2025 | 36 Tage | SEC » |
| 28.02.2025 | 10-K | 31.12.2024 | 59 Tage | SEC » |
| 08.11.2024 | 10-Q | 30.09.2024 | 39 Tage | SEC » |
| 09.08.2024 | 10-Q | 30.06.2024 | 40 Tage | SEC » |
| 07.05.2024 | 10-Q | 31.03.2024 | 37 Tage | SEC » |
| 23.02.2024 | 10-K | 31.12.2023 | 54 Tage | SEC » |
| 03.11.2023 | 10-Q | 30.09.2023 | 34 Tage | SEC » |
| 04.08.2023 | 10-Q | 30.06.2023 | 35 Tage | SEC » |
| 05.05.2023 | 10-Q | 31.03.2023 | 35 Tage | SEC » |
| 23.02.2023 | 10-K | 31.12.2022 | 54 Tage | SEC » |
| 04.11.2022 | 10-Q | 30.09.2022 | 35 Tage | SEC » |
| 05.08.2022 | 10-Q | 30.06.2022 | 36 Tage | SEC » |
| 06.05.2022 | 10-Q | 31.03.2022 | 36 Tage | SEC » |
| 22.02.2022 | 10-K | 31.12.2021 | 53 Tage | SEC » |
| 05.11.2021 | 10-Q | 30.09.2021 | 36 Tage | SEC » |
| 30.07.2021 | 10-Q | 30.06.2021 | 30 Tage | SEC » |
| 30.04.2021 | 10-Q | 31.03.2021 | 30 Tage | SEC » |
| 23.02.2021 | 10-K | 31.12.2020 | 54 Tage | SEC » |
| 05.11.2020 | 10-Q | 30.09.2020 | 36 Tage | SEC » |
| 31.07.2020 | 10-Q | 30.06.2020 | 31 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 11.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 06.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 09.11.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 29.09.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 22.09.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain officers… |
| 29.03.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain officers… |
| 23.03.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain officers… |
| 08.03.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain officers… |
| 30.04.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Compensatory Arrangements of Certain Officers. On April 30, 2020, CryoLife, Inc. (the "Company") announced… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-04-08 | 121 | 35,22 | 4.262 |
| 2026-03-25 | 2.665 | 35,70 | 95.141 |
| 2026-03-23 | 8 | 35,31 | 282 |
| 2026-03-17 | 16.174 | 37,40 | 604.908 |
| 2026-03-06 | 27 | 37,86 | 1.022 |
| 2026-02-20 | 85.352 | 38,00 | 3.243.376 |
| 2026-01-05 | 40 | 44,46 | 1.778 |
| 2025-12-26 | 195 | 46,89 | 9.144 |